Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7383-7389

  Jiang, Hao ^a   Zhao, Wei ^a   Shao, Wei ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

CD44; CD44v6; Hazard ratio; Meta analysis; Non small cell lung cancer; Prognosis

Indexed keywords

CD44 PROTEIN, HUMAN; CD44V6 ANTIGEN; HERMES ANTIGEN;

CHEMISTRY; HUMAN; LUNG TUMOR; META ANALYSIS; MORTALITY; NON SMALL CELL LUNG CANCER; PHYSIOLOGY; PROGNOSIS; PUBLISHING;

ANTIGENS, CD44; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PUBLICATION BIAS;

EID: 84922393824     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2150-3     Document Type: Review

References (32)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.
2. Jett JR, Scott WJ, Rivera MP, Sause WT. American College of Chest Physicians. Guidelines on treatment of stage IIIB nonsmall cell lung cancer. Chest. 2003;123:221S–5S.
3. Alberg A, Ford J, Samet J. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007;132:29S–55S.
4. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.
5. Gunthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24.
6. Wang SJ, Wong G, De Heer AM, Xia W. Bourguignon LY.CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009;119:1518–30.
7. Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, et al. CD44 variant exon 6 expressions in colon cancer assessed by quantitative analysis using real time reverse transcriptase-polymerase chain reaction. Oncol Rep. 2003;10:1919–24.
8. Afify AM, Craig S, Paulino AF, Stern R. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol. 2005;9:312–8.
9. Afify AM, Ferguson AW, Davila RM, Werness BA. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Appl Immunohistochem Mol Morphol. 2001;9:309–14.
10. Dong WG, Sun XM, Yu BP, Luo HS, Yu JP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol. 2003;9:2596–600.
11. Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.
12. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.
13. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–71.
14. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
15. Clarke MR, Landreneau RJ, Resnick NM, Crowley R, Dougherty GJ, Cooper DL, et al. Prognostic significance of CD44 expression in adenocarcinoma of the lung. J Clin Pathol Mol Pathol. 1995;48:M200–4.
16. Leung ELH, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLos One. 2010;5:e14062. doi:10.1371/journal.pone.0014062.
17. Sterlacci W, Savic S, Fiegl M, Obermann E, Tzankov A. Putative stem cell markers in non–small-cell lung cancer a clinicopathologic characterization. J Thorac Oncol. 2014;9:41–9.
18. Takanami I, Takeuchi K, Naruke M. Expression and prognostic value of the standard CD44 protein in pulmonary adenocarcinoma. Oncol Rep. 2000;7:1065–7.
19. Ko YH, Won HS, Jeon EK, Hong SH, Roh SY, Hong YS, et al. Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer. 2011;11:340.
20. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H. Expression of CD44 variant Exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res. 1998;58:1108–10.
21. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases. Cancer. 1999;86:1174–81.
22. Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, Jeffrey RR. Expression of CD44v6 but not E-cadherin or b-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol. 2000;192:427–32.
23. Situ D, Long H, Lin P, Zhu Z, Wang J, Zhang X, et al. Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol. 2010;136:1213–9.
24. Sun BS, Li Y, Zhang ZF, Wang CL. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg. 2013;96:1943–51.
25. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.
26. Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, Yamada A, et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci. 2009;100:2054–9.
27. Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol. 1997;28:809–14.
28. Pirinen R, Hirvikoski P, Böhm J, Kellokoski J, Moisio K, Virén M, et al. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol. 2000;3:1088–95.
29. Nguyen VN, Mirejovský T, Melinová L, Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma. 2000;47:400–8.
30. Carbognani P, Spaggiari L, Romani A, Solli P, Corradi A, Cantoni AM, et al. Expression of human CD44v6 in non-small-cell lung cancer. Eur Surg Res. 1998;30:403–8.
31. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non -small cell lung cancers. Clin Cancer Res. 2006;12:1507–14.
32. Eren B, Sar M, Oz B, Dincbas FH. MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas. Ann Acad Med Singap. 2008;37:32–9.